Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 4/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.46 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6535913 | 0.81 | CYSLTR1 (0.46) | CYP1A2CYSLTR1CYSLTR2GPBAR1NPC1 | |
| SCHEMBL5510083 | 0.81 | CYSLTR1 (0.46) | CYP1A2CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL5093242 | 0.81 | CYP1A2 (0.46) | CYP1A2CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL8754671 | 0.81 | CYSLTR1 (0.46) | CYP1A2CYSLTR1CYSLTR2GPBAR1NPC1 | |
| SCHEMBL8754663 | 0.81 | CYSLTR1 (0.46) | CYP1A2CYSLTR1CYSLTR2GPBAR1NPC1 | |
| SCHEMBL456812 | 0.81 | CYP1A2 (0.46) | CYP1A2CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL6525088 | 0.80 | CYSLTR1 (0.52) | CYP1A2CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL17500352 | 0.80 | CYSLTR1 (0.49) | CYP1A2CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL17227498 | 0.79 | CYSLTR1 (0.50) | CYP1A2CYSLTR1CYSLTR2GPBAR1NPC1 | |
| SCHEMBL1415221 | 0.77 | CYSLTR1 (0.42) | CYP1A2CYSLTR1CYSLTR2GPBAR1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007126865-A2 | LEUKOTRIENE ANTAGONISTS VIA NASAL DRUG DELIVERY | PATRIN PHARMA (US) | 2007-11-08 | — | — | WO | claimed |
| EP-1954679-B1 | A NEW INTERMEDIATE FOR MAKING MONTELUKAST AND RELATED COMPOUNDS | SYNTHON BV (NL) | 2011-02-02 | — | — | EP | disclosed |
| US-7829716-B2 | decyclization of {3-[(E)-2(7-chloro-2-quinolinyl)vinyl]phenyl}-4,5-dihydro-3H-benzo[c]thiepin-1-one by methylmagnesium halide with following conversion to montelukast | Synthon Pharmaceuticals, Inc. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7786138-B2 | Process for making montelukast and intermediates therefor | SYNTHON BV (NL) | 2010-08-31 | — | — | US | disclosed |
| US-20100099879-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | BENOVSKY PETR | 2010-04-22 | — | — | US | disclosed |
| EP-1740545-B1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2010-03-24 | — | — | EP | disclosed |
| US-7601741-B2 | Process for making montelukast and intermediates therefor | SYNTHON BV (NL) | 2009-10-13 | — | — | US | disclosed |
| US-20090093636-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | BENOVSKY PETR | 2009-04-09 | — | — | US | disclosed |
| US-7476748-B2 | Process for making montelukast and intermediates therefor | SYNTHON BV (NL) | 2009-01-13 | — | — | US | disclosed |
| EP-1960362-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | Synthon B.V. (NL) | 2008-08-27 | — | — | EP | disclosed |
| US-5270324-A | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-12-14 | — | — | US | disclosed |
| US-5262429-A | CARDIOTONIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1993-11-16 | — | — | US | disclosed |
| WO-1993021159-A1 | QUINOLINE DERIVATIVES AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-10-28 | — | — | WO | disclosed |
| EP-0565185-A1 | Quinoline derivatives as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1993-10-13 | — | — | EP | disclosed |
| US-5225558-A | Cardiovascular disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1993-07-06 | — | — | US | disclosed |
| CN-1061594-A | Hydroxyalkyl quinoline ether acid as leukotriene antagonists | MERCK FROSST CANADA INT (CA) | 1992-06-03 | — | — | CN | disclosed |
| EP-0480716-A1 | Saturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
| EP-0480716-A1 | Saturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
| EP-0480717-A1 | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
| EP-0480717-A1 | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093636-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | CYP4A11, CYP51A1, CYP4F11 | CYP1A2 467/4885CYSLTR1 9/4885CYSLTR2 19/4885 |
| US-20100099879-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | CMA1, CYP51A1, NOTUM | CYP1A2 580/4885CYSLTR1 5/4885CYSLTR2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.